Hospital in Spain First to Treat Skin Cancer Patients with Esteya Electronic
Hospital La Fe's study demonstrates user- and patient-friendliness and short
procedure time with Esteya
VALENCIA, Spain, Nov. 5, 2013
VALENCIA, Spain, Nov.5, 2013 /PRNewswire/ --Hospital La Fe, a long-time
clinical collaborator of Nucletron, an Elekta company, is nearing the
conclusion of the enrollment phase of a clinical study with the new Esteya®
electronic brachytherapy system for treating skin cancer. First clinical data
on efficacy are expected in about two months, but physicians in the center's
radiotherapy department already are reporting that patients have tolerated the
treatments well and that the system is very user-friendly.
The enrollment of the first group of 20 patients ever to receive treatment
with Esteya, was completed in October. The center is using a standard
treatment protocol of 36.6 Gy over six fractions, 6.1 Gy per fraction
delivered twice weekly.
"The patients have accepted the treatment very well and side effects reported
for the first treated patients have been very mild, typically just little skin
reddening or itching," says José Perez-Calatayud, Head of Medical Physics at
Hospital La Fe. "The treatment delivery times have averaged less than three
minutes per lesion, for a total treatment session of seven to eight minutes.
This short therapy delivery is important, certainly, for patients with
multiple lesions. One of the patients we treated had nine lesions."
"With five surface applicators ranging in size from 1 cm to 3 cm, we have a
great opportunity to adapt to the lesion's size, thus helping us avoid
exposing normal tissue," Perez-Calatayud adds. "And the leakage dose – the
dose outside the volume to be treated – is extremely low due to the
combination of low energy and tungsten shielding of the applicators."
Planning and delivery of electronic brachytherapy at Hospital La Fe has been
"The graphical user interface is uncomplicated and patient set-up is quite
simple, contributing to a smooth, efficient workflow," he says.
For more information, visit www.Esteya.com.
Availability of Esteya in identified markets is subject to regulatory
For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: firstname.lastname@example.org
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management,
Tel: +1 770-670-2447, email: email@example.com
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow
enhancing software systems across the spectrum of cancer care. Stretching the
boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare
providers and patients, Elekta aims to improve, prolong and even save patient
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,500 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker STO:EKTAB. Website:
Press spacebar to pause and continue. Press esc to stop.